FLT3 and graft versus host disease: Conditioning regimens, maintenance therapies after transplantation—such as anti-CD20 antibodies, immunomodulatory drugs, and FLT3 inhibitors, presence and treatment of graft-versus-host disease, and persistent hypogammaglobulinemia are the main factors negatively affecting immune response following vaccination of HSCT recipients [4,8].